The news that Neos Therapeutics’ new ADHD treatment got approved by the FDA made the company’s share values soar to unexpected levels. The small company from Blue Bell, Texas, developed an orally-ingested pill that dissolves almost immediately and provides more or less the same effects as previous treatments.
The pill in question is named Adzenys XR-ODT and it comes in 6 types, the variations depending on dosage strengths, with each and every type corresponding with the same variation in Adderall XR dosages. The clinical trials involving Adzenys showed that the pill in question is bioequivalent to Adderall in terms of effectiveness and viability.
Adzenys XR-ODT functions by having amphetamine doses applied to resin particles which have an immediate release and are coated with polymers. This type of treatment was patented by Neos Therapeutics and is not an alteration of previous amphetamine dispersing pills like MAS-XR capsules which have an extended release. The pill takes around 30 seconds to dissolve in the subject’s mouth, dismissing the usual requirement of swallowing the tablet whole.
Methylphenidate and amphetamine are common treatments for patients suffering from ADHD. Orally ingested pills that dissolve in the patient’s system have the dosage required for one day. The main difference between traditional treatments for ADHD in the form of tablets and ODTs like Adzenys is the fact that the latter tablets dissolve in the patient’s mouth immediately after being taken, instead of passing through the subject’s system in order to reach the stomach.
The reason why Neos Therapeutics developed this pills stems from the fact that some people are not able to swallow whole pills. This is extensively viable in regards to children suffering from ADHD, with parents commonly hiding pills in applesauce or other foods in order for the child to swallow the pill unknowingly. This requirement is effectively removed in the case of Adzenys XR-ODT, being the first tablet for ADHD that dissolves in one’s mouth.
In order to give doctors and parents an option in regards to ADHD treatments by using ODT types of pills, Neos is currently focusing on the development of a pill similar to Adzenys which will shift from amphetamine use to methylphenidate. This pill is expected to launch by the year of 2017, but that date may change depending on clinical trials, as well as the FDA’s decision in regards to the new pill’s viability.
Due to the fact that a new ADHD treatment got approved by the FDA, parents will have yet another option to treat their offsprings’ ADHD. The pill can be administered to kids above the age of 6.